Table 2 Prostate biopsy outcomes for men ≤55 years compared to men >55 years
Factor | Age ≤55 years | Age >55 years | Total | Significance |
|---|---|---|---|---|
Insignificant prostate cancer (Epstein criteria) | 13 (14.0 %) | 60 (11.9 %) | 73 (12.2 %) | X2 = 0.32, p = 0.57 |
Total | 93 | 505 | 598 | |
Gleason score | ||||
>6 | 61 (65.6 %) | 370 (73.3 %) | 431 (72.1 %) | X2 = 2.3, p = 0.13 |
>7 | 9 (9.7 %) | 70 (13.9 %) | 79 (13.2 %) | X2 = 1.2, p = 0.27 |
Continuous variable | Mean = 2.03 | Mean = 2.23 | t = −1.53 | |
Std dev = 1.05 | Std dev = 1.15 | p = 0.13 | ||
Mean difference = −0.20 | ||||
95 % CI of difference = −0.45 to 0.06 | ||||
PSA comparison | Mean = 8.55 | Mean = 7.10 | t = 0.977 | |
Std dev = 14.26 | Std dev = 3.98 | p = 0.33 | ||
Std error mean =1.48 | Std error mean =0.18 | Mean difference = 1.45 | ||
95 % CI of difference = −1.50 to 4.41 | ||||
High risk PC | ||||
GS > 7 | 9 (12.5 %) | 70 (13.9 %) | 79 (13.2 %) | X2 = 1.2, p = 0.27 |
PSA > 20 | 3 (3.2 %) | 6 (1.2 %) | 9 (1.5 %) | X2 = 2.2, p = 0.14 |
Clinical stage > T2b | 14 (15.1 %) | 74 (14.7 %) | 88 (14.7 %) | X2 = 0.03, p = 0.86 |
At least one feature of high risk PC | 23 (24.7 %) | 127 (25.1 %) | 150 (25.1 %) | X2 = 0.007, p = 0.93 |